1-2 of 2
Michele Schoenwald, MD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Pegylated Interferon a2a (PegIFN) At the Dose of 45μg Per Week in Combination with Imatinib 400mg Is the Recommended Initial Dose for Patients (pts) with Chronic Phase Chronic Myeloid Leukemia (CML-CP): Results From the French SPIRIT Trial of the French CML Group (FI LMC)

Hyacinthe Johnson-Ansah, MD, Joelle Guilhot, Philippe Rousselot, MD, PhD, Rea Delphine, MD, PhD, Francoise Rigal-Huguet, MD, Franck E. Nicolini, MD, PhD, Anne Vekhoff, MD, Agnès Guerci-Bresler, MD, PhD, Michele Schoenwald, MD, Eric Jourdan, Laurence Legros, Valérie Coiteux, MD, Francois-Xavier Mahon, MD, PhD, Claude Preudhomme, Francois Guilhot
Journal: Blood
Blood (2011) 118 (21): 456.
https://doi.org/10.1182/blood.V118.21.456.456
Published: 2011
Journal Articles

Randomized Comparison of Imatinib Versus Imatinib Combination Therapies in Newly Diagnosed Chronic Myeloid Leukaemia (CML) Patients in Chronic Phase (CP): First Results of the Phase III (SPIRIT) Trial from the French CML Group (FI LMC)

Francois Guilhot, MD, François-Xavier Mahon, MD, PhD, Joelle Guilhot, MSci, Francoise Rigual-Huguet, MD, Frederic Maloisel, MD, Philippe Rousselot, MD, PhD, Martine Gardembas, MD, Selim Corm, MD, Agnes Guerci, MD, PhD, Anne Vekhoff, MD, Gabriel Etienne, MD, Laurence Legros, MD, Jean- Jacques Kiladjian, MD, PhD, Eric Jourdan, Michele Schoenwald, MD, Marc Berger, MD, Virginie Eclache, MD, Catherine Roche-Lestienne, PhD, Franck E Nicolini, MD, PhD, Claude Preudhomme, MD, PhD
Journal: Blood
Blood (2008) 112 (11): 183.
https://doi.org/10.1182/blood.V112.11.183.183
Published: 2008